Trademark: 79352355
Status Date
Tuesday, April 9, 2024
Registration Number
7349426
Registration Date
Tuesday, April 9, 2024
Filing Date
Monday, August 1, 2022
Published for Opposition
Tuesday, January 23, 2024
5 Viral systems comprised of viral vectors combined with antibodies; gene therapy systems comprised of viral vectors combined with antibodies; nucleic acid delivery systems being therapeutic agents for delivery to human tissue namely viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors or nucleic acid delivery vectors for medical purposes; pharmaceutical products for the treatment of neuro degenerative and neuromuscular disorders being autoimmune diseases; biological preparations for the treatment neuro degenerative and neuromuscular disorders being autoimmune diseases; biological preparations for use in medical and clinical gene therapy, nucleic acid-based therapy and cell therapy for the treatment of neuro degenerative and neuromuscular disorders being autoimmune diseases; clinical medical reagents for use in nucleic acid-based therapy, cell therapy, pharmaceutical preparations, prophylaxis products preparations and other pharmaceutical products preparations and other pharmaceutical products preparations for use in nucleic acid-based therapy, gene therapy for the treatment of neuro degenerative and neuromuscular disorders being autoimmune diseases
44 Medical treatment by gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation for metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders, inherited disorders, genetic disorders and single gene disorders; consultancy in the field of pharmaceutics
42 Scientific and medical research, product development and consultancy in the field of biotechnology, biologics, medical science, chemistry and biochemistry; Scientific and medical research and product development in the field of pharmaceutics
Apr 9, 2024
Registered-Principal Register
Apr 9, 2024
Notice Of Registration Confirmation Emailed
Apr 1, 2024
Notification Of Possible Opposition - Processed By Ib
Mar 13, 2024
Notification Of Possible Opposition Sent To Ib
Mar 13, 2024
Notification Of Possible Opposition Created, To Be Sent To Ib
Jan 23, 2024
Official Gazette Publication Confirmation E-Mailed
Jan 23, 2024
Published For Opposition
Jan 22, 2024
Notification Processed By Ib
Jan 3, 2024
Notification Of Possible Opposition Sent To Ib
Jan 3, 2024
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Jan 3, 2024
Notification Of Notice Of Publication E-Mailed
Dec 18, 2023
Approved For Pub - Principal Register
Dec 12, 2023
Examiner's Amendment Entered
Dec 12, 2023
Notification Of Examiners Amendment E-Mailed
Dec 12, 2023
Examiners Amendment E-Mailed
Dec 12, 2023
Examiners Amendment -Written
Dec 8, 2023
Teas/Email Correspondence Entered
Dec 7, 2023
Correspondence Received In Law Office
Dec 7, 2023
Teas Response To Office Action Received
Jul 22, 2023
Refusal Processed By Ib
Jun 27, 2023
Non-Final Action Mailed - Refusal Sent To Ib
Jun 27, 2023
Refusal Processed By Mpu
May 20, 2023
Non-Final Action (Ib Refusal) Prepared For Review
May 19, 2023
Non-Final Action Written
May 18, 2023
Assigned To Examiner
Apr 11, 2023
New Representative At Ib Received
Oct 18, 2022
Application Filing Receipt Mailed
Oct 14, 2022
New Application Office Supplied Data Entered
Oct 13, 2022
Sn Assigned For Sect 66a Appl From Ib
Trademark Alertz updated from USPTO on 2030-01-24
